Table 3 Estimates of factors associated with pain over time in mixed-effects models in pre-intervention and Phase I implementation cohorts
Univariate* | Multivariate | |||
|---|---|---|---|---|
β (95% CI) | p-value | β (95% CI) | p-value | |
Male Sex | −1.74 (− 2.22,-1.26) | < 0.01 | − 0.49 (− 0.83,-0.15) | < 0.01 |
Public insurance | 0.37 (− 0.14,0.87) | 0.16 | – | – |
Baseline pain | 0.58 (0.51,0.65) | < 0.01 | 0.38 (0.31,0.45) | < 0.01 |
Incident diagnosis* | 0.91 (0.26,1.37) | < 0.01 | − 0.59 (− 0.94,-0.24) | < 0.01 |
cJADAS # | 0.39 (0.35,0.43) | < 0.01 | 0.31 (0.27,0.35) | < 0.01 |
Time (in months) | −0.02 (− 0.05, 0.01) | 0.28 | 0.00 (− 0.02, 0.02) | 0.65 |
Tender entheses count # | 0.38 (0.29,0.48) | < 0.01 | – | – |
DMARD use # | 0.09 (− 0.45,0.63) | 0.73 | – | – |
Biologic use | − 0.37 (− 0.83,0.09) | 0.12 | – | – |
Pre-intervention vs Phase I cohort | 0.49 (− 0.09,1.07) | 0.10 | – | – |
Pre/post Phase I cohort * time interaction^ | −0.03 (− 0.17,0.11) p | 0.67 | – | – |